Randomized Trialhigh evidence
Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials.
Nature medicine·November 2, 2026·PMID 42972109
Why it mattersNonsegmental vitiligo has limited systemic treatment options, and many patients seek repigmentation. These trials provide high-level evidence that an oral JAK1 inhibitor can produce clinically meaningful facial repigmentation, offering a potential new therapeutic class for patients who are candidates for systemic therapy.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled